News and Updates
TAVR patients on DAPT at higher risk of bleeding events
Transcatheter aortic valve replacement (TAVR) patients who are discharged with dual antiplatelet therapy (DAPT) may have a significantly higher risk of major bleeding events vs. patients who are discharged with antiplatelet monotherapy, according to a study published in the American Heart Journal. Rates of death, stroke and myocardial infarction at one year were similar between patients on DAPT and those on monotherapy. However, patients on DAPT had a significantly higher risk of major bleeding events.
Read the full story.
Create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies